Also known as: Novo, Novo Nordisk
Novo Nordisk is a global healthcare company focused on defeating serious chronic diseases, especially diabetes and obesity. The company is active in more than 80 countries and markets products in about 170 countries worldwide.
Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Novo Nordisk and AWS announced a strategic AI partnership for drug discovery, including a London co-innovation hub. AWS is now the preferred cloud provider, with productivity gains for 25,000 employees.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Biotech funding roundup: $8M CIRM grant to Siren, $3.5M pre-seed for Claryx, Syntax Bio's $14.4M Series A, €80M Novo Nordisk Foundation programme, and Appili's NIAID contract termination.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07815067 |
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07808788 |
A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function |
NOT_YET_RECRUITING | PHASE1 |
| NCT07797855 |
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People |
NOT_YET_RECRUITING | PHASE1 |
| NCT07797335 |
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications |
RECRUITING | PHASE3 |
| NCT07781371 |
A Retrospective Real-World Cohort Study |
NOT_YET_RECRUITING | |
| NCT07770841 |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
RECRUITING | PHASE3 |
| NCT07769489 |
Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance |
NOT_YET_RECRUITING | PHASE1 |
| NCT07767175 |
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity |
RECRUITING | PHASE1 |
| NCT07757087 |
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo |
RECRUITING | PHASE1 |
| NCT07745504 |
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight |
RECRUITING | PHASE3 |
